Department of Surgery - Otolaryngology, The University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne St RVEEH, Melbourne East 3002,Victoria, Australia; Cochlear Implant Clinic, Royal Victorian Eye and Ear Hospital, 32 Gisborne St, Melbourne East 3002, Australia.
Department of Surgery - Otolaryngology, The University of Melbourne, Royal Victorian Eye and Ear Hospital, 32 Gisborne St RVEEH, Melbourne East 3002,Victoria, Australia; Department of Otorhinolaryngology - Head & Neck Surgery, Ansan Hospital, College of Medicine, Korea University, 123, Jeokgeum-ro (Street), Gojan-dong, Danwon-gu, Ansan-si, Gyeonggi-do 15355, Republic of Korea.
Hear Res. 2021 May;404:108224. doi: 10.1016/j.heares.2021.108224. Epub 2021 Feb 28.
To assess whether a single, peri-operative, high dose of methylprednisolone can improve the preservation of residual acoustic hearing following cochlear implantation (CI).
This was a double blinded placebo-controlled trial, performed in a tertiary academic centre. The hypothesis was that methylprednisolone would improve the preservation of hearing, and lower electrode impedances. Adult patients (18-85 years) with hearing at 85 dB or better at 500 Hz in the ear to be implanted were randomly allocated to either treatment (methylprednisolone, 1g administered intravenously upon induction of anaesthesia) or control (normal saline infusion). As per standard clinical practice, all patients received a routine dose of dexamethasone (8 mg intravenously) on induction of anaesthesia. Implantation was undertaken with a slim and flexible lateral wall electrode via the round window. Surgical technique was routine, with adherence to soft surgical principles. The primary outcome was hearing preservation within 20 dB at 500 Hz, 12 months following cochlear implantation. Secondary outcomes included hearing preservation at 6 weeks and 3 months, monopolar electrode impedance, and Consonant-Vowel-Consonant (CVC) Phoneme scores at 3 and 12 months after surgery.
Forty-five patients were enrolled into the control group and 48 patients received the steroid. The number of patients achieving hearing preservation at 12 months did not differ significantly between those receiving methylprednisolone treatment and the controls. There were no differences in hearing preservation at any frequency at either 6 weeks or 3 months after implantation. Neither CVC phoneme scores nor electrode impedances differed between the groups.
This paper demonstrates that high-dose local steroid injection at surgery was not effective in preventing a loss of residual hearing, improving speech perception, or lowering electrode impedances. The findings were contrary to the experimental literature, and emerging clinical evidence that steroid elution from implant electrodes influences cochlear biology in humans. We found no evidence to support the widely-held practice of administering intravenous steroids in the perioperative period, in an attempt to preserve residual hearing.
评估单次围手术期大剂量甲泼尼龙能否改善人工耳蜗植入(CI)后残余听力的保留。
这是一项在三级学术中心进行的双盲安慰剂对照试验。假设甲泼尼龙可以改善听力保留,并降低电极阻抗。在植入耳听力为 500 Hz 时为 85 dB 或更好的成年患者(18-85 岁)被随机分配至治疗组(麻醉诱导时静脉注射 1 克甲泼尼龙)或对照组(生理盐水输注)。按照标准临床实践,所有患者在麻醉诱导时静脉注射常规剂量地塞米松(8 mg)。通过圆窗植入细而灵活的侧壁电极。手术技术是常规的,遵循软手术原则。主要结局是人工耳蜗植入后 12 个月时 500 Hz 听力保留在 20 dB 以内。次要结局包括 6 周和 3 个月时的听力保留、单极电极阻抗以及术后 3 个月和 12 个月的 CVC 音素评分。
45 例患者纳入对照组,48 例患者接受类固醇治疗。在接受甲泼尼龙治疗和对照组的患者中,12 个月时听力保留的患者数量无显著差异。植入后 6 周和 3 个月时,各频率的听力保留均无差异。两组间 CVC 音素评分或电极阻抗无差异。
本文表明,手术时局部大剂量类固醇注射不能有效防止残余听力损失、改善言语感知或降低电极阻抗。这些发现与实验文献和新兴的临床证据相矛盾,后者表明,从植入电极洗脱的类固醇会影响人类的耳蜗生物学。我们没有证据支持在围手术期广泛应用静脉类固醇来试图保留残余听力的做法。